Partial immune reconstitution following highly active antiretroviral therapy: Can adjuvant interleukin-2 fill the gap?

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 4, 2005, Pages 401-409

  Marchetti, Giulia ^a   Franzetti, Fabio ^a   Gori, Andrea ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

HAART; HIV; IL 2; Immune reconstitution; Immunotherapy

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL INTERACTION; CELL SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; IMMUNOTHERAPY; IN VITRO STUDY; INFECTION CONTROL; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; MEDICAL DECISION MAKING; MICROENVIRONMENT; NONHUMAN; SIDE EFFECT; T LYMPHOCYTE; TREATMENT PLANNING; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHEMOTHERAPY, ADJUVANT; HIV INFECTIONS; HUMANS; INTERLEUKIN-2;

EID: 17444385673     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh557     Document Type: Article

References (70)

1. Palella, F. J., Jr, Delaney, K. M., Moorman, A. C. et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 338, 853-60.
2. Ippolito, G., Galati, V., Serraino, D. et al. (2001). The changing picture of the HIV/AIDS epidemic. Annals of the New York Academy of Sciences 946, 1-12.
3. Pitcher, C. J., Quittner, C., Peterson, D. M. et al. (1999). HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Medicine 5, 518-25.
4. Leibowitz, M. R. & Mitsuyasu, R. T. (2001). Immune reconstitution strategies in HIV. Current Infectious Disease Reports 3, 302-8.
5. Piketty, C., Castiel, P., Belec, L. et al. (1998). Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 12, 745-50.
6. Renaud, M., Katlama, C., Mallet, A. et al. (1999). Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimens. AIDS 13, 669-76.
7. Connick, E., Lederman, M., Kotzin, B. et al. (2000). Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. Journal of Infectious Diseases 181, 358-63.
8. Notermans, D., Pakker, N., Hamann, D. et al. (1999). Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency type-1 infected adults. Journal of Infectious Diseases 180, 1050-6.
9. Wu, H., Kuritzkes, D., McClernon, D. et al. (1999). Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. Journal of Infectious Diseases 179, 799-807.
10. Douek, D. C. (2003). Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Reviews 5, 172-7.
11. Lederman, M. M. & Valdez, H. (2000). Immune restoration with antiretroviral therapies: implications for clinical management. Journal of the American Medical Association 284, 223-8.
12. Fumero, E., Garcia, F. & Gatell, J. M. (2004). Immunosuppressive drugs as an adjuvant to HIV treatment. Journal of Antimicrobial Chemotherapy 53, 415-7.
13. Bahr, G. M. (2003). Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide. Journal of Antimicrobial Chemotherapy 51, 5-8.
14. Gori, A., Trabattoni, D., Bandera, A. et al. (2004). Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial. Antiviral Therapy 9, 603-14.
15. Bagby, G. & Heinrich, M. (2000). Growth factors, cytokines, and the control of hematopoiesis. In Hematology Basic Principles and Practice, 3rd edn, pp. 154-202. Churchill Livingstone, Philadelphia, PA, USA.
16. Kovacs, J. A., Vogel, S., Albert, J. M. et al. (1996). Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. New England Journal of Medicine 335, 1350-6.
17. Davey, R. T., Jr, Chaitt, D. G., Albert, J. M. et al. (1999). A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. Journal of Infectious Diseases 179, 849-58.
18. Levy, Y., Capitant, C., Houhou, S. et al. (1999). Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet 353, 1923-9.
19. Hengge, U. R., Goos, M., Esser, S. et al. (1998). Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 12, F225-34.
20. Davey, R., Murphy, R., Graziano, F. et al. (2000). Immunologic and virologic effects of subcutaneous interleukin-2 in combination with antiretroviral therapy. Journal of the American Medical Association 284, 183-9.
21. Arnò, A., Ruiz, L., Juan, M. et al. (1999). Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load. Journal of Infectious Diseases 180, 56-60.
22. David, D., Nait-Ighil, L., Dupont, B. et al. (2001). Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. Journal of Infectious Diseases 183, 730-5.
23. Marchetti, G., Meroni, L., Varchetta, S. et al. (2002). Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. Journal of Infectious Diseases 186, 606-16.
24. Katlama, C., Carcelain, G., Duvivier, C. et al. (2002). Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study - ANRS 082. AIDS 16, 2027-34.
25. Mitsuyasu, R. (2002). Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients. Journal of Infectious Diseases 185, Suppl. 2, S115-22.
26. Sereti, I. & Lane, H. C. (2001). Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies. Clinical Infectious Diseases 32, 1738-55.
27. SILCAAT study design. [Online.] http://www.iatec.com/index2.html (29 October 2004, date last accessed).
28. ESPRIT IL-2 Trial. [Online.] http://www.espritstudy.org (29 October 2004, date last accessed).
29. Tambussi, G., Ghezzi, S., Nozza, S. et al. (2001). Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. Journal of Infectious Diseases 183, 1476-84.
30. Autran, B., Carcelain, G., Li, T. S. et al. (1999). Restoration of the immune system with anti-retroviral therapy. Immunology Letters 66, 207-11.
31. d'Arminio Monforte, A., Testori, V., Adorni, F. et al. (1999). CD4 cell counts at the third month of HAART may predict clinical failure. AIDS 13, 1669-76.
32. Barni, S., Lissoni, P., Cazzaniga, M. et al. (1995). A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 52, 243-5.
33. Lissoni, P., Barni, S., Brivio, F. et al. (1995). Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study. Journal of Biological Regulators and Homeostatic Agents 9 52-4.
34. Bordin, V., Giani, L., Meregalli, S. et al. (2000). Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. Urologia Internationalis 64, 3-8.
35. Lissoni, P., Bolis, S., Brivio, F. et al. (2000). A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Anticancer Research 20, 2103-5.
36. Lange, C. G. & Lederman, M. M. (2003). Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. Journal of Antimicrobial Chemotherapy 51, 1-4.
37. Lori, F., Maserati, R., Foli, A. et al. (2000). Structured treatment interruptions to control HIV-1 infection. Lancet 354, 287-8.
38. 3 as the threshold for restarting HAART. In Program and Abstracts of the Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004. Abstract 510, p. 248. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
39. 3 to restart HAART (ACTG A5102). In Program and Abstracts of the XV International AIDS Conference, Bangkok, Thailand, 2004. Abstract TuPeB4585, p. 364. International AIDS Society, Geneva, Switzerland.
40. Rosenberg, E. S., Altfeld, M., Poon, S. H. et al. (2000). Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523-6.
41. Hecht, F., Kahn, J., Martinez-Marino, B. et al. (2002). Interleukin-2 (IL-2) added to HAART in primary HIV infection enhances anti-HIV immune responses. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002. Abstract 527-M, p. 249. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
42. Hecht, F., Hare, C., McGrath, M. et al. (2003). Interleukin-2 in conjunction with HAART in early HIV infection increases naive and memory CD4 cells and lowers activation markers. In Program and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2003. Abstract 649, p. 290. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
43. Natarajan, V., Lempicki, R. A., Sereti, I. et al. (2002). Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. Proceedings of the National Academy of Sciences USA 99, 10712-7.
44. Sereti, I., Anthony, K. B., Martinez-Wilson, H. et al. (2004). IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 104, 775-80.
45. Sereti, I., Herpin, B., Metcalf, J. et al. (2001). CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. AIDS 15 1765-75.
46. De Paoli, P., Bortolin, M., Zanussi, S. et al. (2001). Changes in thymic function in HIV-positive patients treated with highly active antiretroviral therapy and interleukin-2. Clinical and Experimental Immunology 125, 440-6.
47. Carcelain, G., Saint-Mezard, P., Altes, H. K. et al. (2003). IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia. AIDS 17, 841-50.
48. Sereti, I., Sklar, P., Ramchandani, M. et al. (2004). Increased immune activation is associated with decreased responsiveness to in vivo IL-2 administration. In Program and Abstracts of the Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004. Abstract 213, p. 143. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
49. De Paoli, P., Zanussi, S., Simonelli, C. et al. (1997). Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. Journal of Clinical Investigation 100, 2737-43.
50. Marchetti, G., Meroni, L., Molteni, C. et al. (2004). Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. AIDS 18, 211-6.
51. Marchetti, G., Meroni, L., Molteni, C. et al. (2004). IL-7/IL-7 receptor system regulation following IL-2 immunotherapy in HIV-infected patients. Antiviral Therapy 9, 447-52.
52. Boutboul, F., Puthier, D., Nguyen, C. et al. (2003). Systematic microarray analysis reveals counter balance between perforin and interleukin 7 receptor with progression of HIV infection. In Program and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2003. Abstract 34, p. 69. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
53. Mackall, C. L., Hakin, F. T. & Gress, R. E. (1997). T-cell regeneration: all repertoires are not created equal. Immunology Today 18, 245-51.
54. Ku, C. C., Murakami, M., Sakamoto, A. et al. (2000). Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 288, 675-8.
55. Lenardo, M., Chan, K. M., Hornung, F. et al. (1999). Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment. Annual Review of Immunology 17, 221-53.
56. Caggiari, L., Zanussi, S., Bortolin, M. et al. (2000). Effects of therapy with highly active antiretroviral therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients. Clinical and Experimental Immunology 120, 101-6.
57. Pandolfi, F., Pierdominici, M., Marziali, M. et al. (2000). Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. Clinical Immunology 94, 153-9.
58. Natarajan, V., Bosche, M., Metcalf, J. et al. (1999). HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet 353, 119-20.
59. Hazenberg, M., Verschuren, M., Hamann, D. et al. (2001). T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. Journal of Molecular Medicine 79, 631-40.
60. Mackall, C., Fleisher, T., Brown, M. et al. (1997). Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 89, 3700-7.
61. Fry, T. & Mackall, C. (2002). Interleukin-7: from bench to clinic. Blood 99, 3892-904.
62. Levy, Y., Durier, C., Krzysiek, R. et al. (2003). Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 17, 343-51.
63. Sullivan, A., Hardy, G., Nelson, M. et al. (2003). Interleukin-2 associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy. AIDS 17, 628-9.
64. Valdez, H., Mitsuyasu, R., Landay, A. et al. (2003). Interleukin-2 induces increases in CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. Journal of Infectious Diseases 187, 320-5.
65. Sallusto, F., Lenig, D., Forster, R. et al. (1999). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-12.
66. Markert, M. L., Hicks, C. B., Bartlett, J. A. et al. (2000). Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. AIDS Research and Human Retroviruses 16, 403-13.
67. Nelson, B. H. (2004). IL-2, regulatory T cells, and tolerance. Journal of Immunology 172, 3983-8.
68. Blattman, J., Grayson, J., Wherry, E. et al. (2003). Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nature Medicine 9, 540-7.
69. + HIV-specific T cell immune responses in vitro and are associated with favourable clinical markers of disease status. Journal of Experimental Medicine 200, 331-43.
70. Lederman, H. M., Williams, P. L., Wu, J. W. et al. (2003). Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. Journal of Infectious Diseases 188, 1794-803.